Advertisement

Morbidities Related to Adjuvant Radiotherapy and Chemotherapy

  • Vijay V. Haribhakti
Chapter

Abstract

In this important chapter authored by Drs. Ankita Nachankar and Prasad Dandekar, a detailed account is presented of all the many morbidities that result from these treatments and the strategies possible to manage them in order to minimize complications and sequelae.

Over 60% of all patients treated for head and neck cancer need one or both of these treatments, making it mandatory to strategically minimize complications.

The major morbidities covered include:
  • Radiation dermatitis

  • Radiation mucositis

  • Salivary dysfunction and xerostomia

  • Dysphagia and the importance of “DARS”

  • Aspiration and swallowing maneuvers

  • Trismus and fibrosis

  • Dental effects

  • Osteoradionecrosis

  • Hypothyroidism

  • Toxicities associated with chemotherapy and targeted therapy

In all cases, the pathophysiology, clinical manifestations, preventive and management strategies have been outlined, rendering it an extremely important chapter for all.

References

  1. 1.
    Chaturvedi P (2009) Head and neck surgery. J Can Res Ther 5:143CrossRefGoogle Scholar
  2. 2.
    Kulkarni MR (2013) Head and neck cancer burden in India. Int J Head Neck Surg 4(1):29–35CrossRefGoogle Scholar
  3. 3.
    Forastiere AA, Trotti A (1999) Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 91:2065–2066PubMedCrossRefGoogle Scholar
  4. 4.
    Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V et al (2015) The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population-based analysis by the ESTRO-HERO project. Radiother Oncol 116:45–50PubMedCrossRefGoogle Scholar
  5. 5.
    Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Russi EG, Moretto F, Rampino M et al (2015) Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus. Crit Rev Oncol Hematol 96(1):167–182PubMedCrossRefGoogle Scholar
  7. 7.
    McQuestion M (2006) Evidence-based skin care management in radiation therapy. Sem Oncol Nurs 22(3):163–173CrossRefGoogle Scholar
  8. 8.
    Porock D (2002) Factors influencing the severity of radiation skin and oral mucosal reactions: development of a conceptual framework. Eur J Cancer Care 11:33–43Google Scholar
  9. 9.
    Ratliff C (1990) Impaired skin integrity related to radiation therapy. J Enterostom Ther 17:193–198Google Scholar
  10. 10.
    Denham JW, Hauer-Jensen M (2002) The radiotherapeutic injury – a complex ‘wound’. Radiother Oncol 63:129–145PubMedCrossRefGoogle Scholar
  11. 11.
    Mendelsohn FA, Divino CM, Reis ED et al (2002) Wound care after radiation therapy. Adv Skin Wound Care 15:216–224PubMedCrossRefGoogle Scholar
  12. 12.
    Shell JA, Stanutz F, Grimm J (1986) Comparison of moisture vapor permeable (MVP) dressings to conventional dressings for the management of radiation skin reactions. Oncol Nurs Forum 13:11–16PubMedGoogle Scholar
  13. 13.
    Vilela-Goulart MG, Teixeira RT, Rangel DC, Niccoli-Filho W, Gomes MF et al (2008) Homogenous amniotic membrane as a biological dressing for oral mucositis in rats: histomorphometric analysis. Arch Oral Biol 53:1163–1171PubMedCrossRefGoogle Scholar
  14. 14.
    Gruss JS, Jirsch DW (1978) Human amniotic membrane: a versatile wound dressing. Can Med Assoc J 118:1237–1246PubMedPubMedCentralGoogle Scholar
  15. 15.
    Mohammadi AA, Sabet B, Riazi H, Tavakkolian AR, Mohammadi MK (2009) Human amniotic membrane dressing: an excellent method for outpatient management of burn wounds. Indian J Med Sci 34:1–29Google Scholar
  16. 16.
    Cheng KK, Leung SF, Thompson DR, Tai JW, Liang RH, Kan AS et al (2007) New measure of health-related quality of life for patients with oropharyngeal mucositis: development and preliminary psychometric evaluation. Cancer 109:2590–2599PubMedCrossRefGoogle Scholar
  17. 17.
    Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262PubMedCrossRefGoogle Scholar
  18. 18.
    Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A et al (2011) Interventions for preventing oral mucositis for patients with cancer receiving treatment (review). Cochrane Database Syst Rev 4:CD000978Google Scholar
  19. 19.
    Biswal BM, Zakaria A, Ahmad NM (2003) Topical application of honey in the management of radiation mucositis: a preliminary study 2003. Support Care Cancer 11:242–248PubMedGoogle Scholar
  20. 20.
    Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43PubMedCrossRefGoogle Scholar
  21. 21.
    US Department of Health and Human Services (2009) Common terminology criteria for adverse events (CTCAE) version 4.0. National Cancer Institute 09-5410Google Scholar
  22. 22.
    Bjarnason GA, Mackenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, Leong C, Wilson J, Jordan RC, Walker M, Tu D, Parulekar W (2009) Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys 73(1):166–172PubMedCrossRefGoogle Scholar
  23. 23.
    Nutting CM et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicenter randomized controlled trial. Lancet Oncol 12(2):127–136PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Li K, Yang L, Hu QY, Chen XZ, Chen M, Chen Y (2017) Oral mucosa dose parameters predicting grade ≥3 acute toxicity in locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemotherapy: an independent validation study comparing oral cavity versus mucosal surface contouring techniques. Transl Oncol 10(5):752–759PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Mcguire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, Elad S (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3165–3177PubMedCrossRefGoogle Scholar
  26. 26.
    Dodd MJ, Miaskowski C, Greenspan D, MacPhail L, Shih AS, Shiba G et al (2003) Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt and soda mouthwashes. Cancer Investig 21:21–33CrossRefGoogle Scholar
  27. 27.
    Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, Riesenbeck D (2013) Systematic review of antiinflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3179–3189PubMedCrossRefGoogle Scholar
  28. 28.
    Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H (2002) Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation induced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys 54(2):479–485PubMedCrossRefGoogle Scholar
  29. 29.
    Le QT, Kim HE, Schneider CJ, Murakozy G, Skladowski K, Reinisch S, Chen Y, Hickey M, Mo M, Chen MG, Berger D, Lizambri R, Henke M (2011) Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 29(20):2808–2814PubMedCrossRefGoogle Scholar
  30. 30.
    Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T, Tsugane M (2015) L-Glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep 33(1):33–39PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Leenstra JL, Miller RC, Qin R, Martenson JA, Dornfeld KJ, Bearden JD, Puri DR, Stella PJ, Mazurczak MA, Klish MD, Novotny PJ, Foote RL, Loprinzi CL (2014) Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol 32(15):1571–1577PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Bjordal JM, Bensadoun RJ, Tuner J, Frigo L, Gjerde K, Lopes Martins RA (2011) A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer 19(8):1069–1077PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Carter DL, Herbert ME, Smink K, Brizel DM (1999) Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancer. Head Neck 21:8760–8766CrossRefGoogle Scholar
  34. 34.
    Porter SR, Scully C, Hegarty AM (2004) An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:28–46PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Jenkins G (1966) The physiology of the mouth. In: Jenkins G (ed) The physiology of the mouth, 3rd edn. Blackwell Scientific Publications, Oxford, p 328Google Scholar
  36. 36.
    Dirix P, Nuyts S, Van den Bogaert W (2006) Radiation-induced Xerostomia in patients with head and neck cancer: a literature review. Cancer 107:2525–2534PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Nagler RM (2002) The enigmatic mechanism of irradiation-induced damage to the major salivary glands. Oral Dis 8:141–146PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Konings AW, Coppes RP, Vissink A (2005) On the mechanism of salivary gland radiosensitivity. Int J Rad Oncol Biol Phys 62:1187–1194CrossRefGoogle Scholar
  39. 39.
    Abok K, Brunk U, Jung B, Ericsson J (1984) Morphologic and histochemical studies of the deferring radiosensitivity of the ductular and acinar cell of the rat submandibular gland. Virchows Arch Cell Pathol 45:443–460CrossRefGoogle Scholar
  40. 40.
    Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A (2003) Quality of life after parotid sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 57:61–70PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Henson BS, Inglehart MR, Eisbruch A, Ship JA (2001) Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 37:84–93PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770–3776PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomized controlled trial. Lancet Oncol 12:127–136PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO (2010) Use of normal tissue complication probability models in the clinic. Int J Rad Oncol Biol Phys 76(3):S10–S19CrossRefGoogle Scholar
  45. 45.
    Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP (2003) Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 14:213–225PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Vissink A, Johannes’s-Gravenmade E, Panders AK, Vermey A (1988) Treatment of hyposalivation. Ear Nose Throat J 67:179–185PubMedPubMedCentralGoogle Scholar
  47. 47.
    Momm F, Volegova-Neher N, Schulte-Monting J, Guttenberger R (2005) Different saliva substitutes for treatment of xerostomia following radiotherapy: a prospective crossover study. Strahlenther Onkol 181:231–236PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Sood AJ, Fox NF, O’Connell BP, Lovelace TL, Nguyen SA et al (2014) Salivary gland transfer to prevent radiation-induced xerostomia: a systematic review and meta-analysis. Oral Oncol 50:77–83PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Bensadoun RJ, Schubert MM, Lalla RV, Keefe D (2006) Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer 14:566–572PubMedCrossRefGoogle Scholar
  50. 50.
    Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D (2002) Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 12:4–13PubMedCrossRefGoogle Scholar
  51. 51.
    Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Månsson B (1996) Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 32:182–190CrossRefGoogle Scholar
  52. 52.
    Lombaert IM, Brunsting JF, Wierenga PK, Faber H, Stokman MA et al (2008) Rescue of salivary gland function after stem cell transplantation in irradiated glands. PLoS One 3:2063CrossRefGoogle Scholar
  53. 53.
    Alevizos I, Zheng C, Cotrim AP, Liu S, McCullagh L, Billings ME et al (2017) Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction. Gene Ther 24:176–186PubMedCrossRefGoogle Scholar
  54. 54.
    Logemann JA, Rademaker AW, Pauloski BR et al (2006) Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck 28(1):64–73PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Langerman A et al (2007) Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 133(12):1289–1295PubMedCrossRefGoogle Scholar
  56. 56.
    Mortensen HR, Jensen K, Grau C (2013) Aspiration pneumonia in patients treated with radiotherapy for head and neck cancer. Acta Oncol 52(2):270–276PubMedCrossRefGoogle Scholar
  57. 57.
    Chen AY et al (2001) The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the MD Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 127:870–876PubMedGoogle Scholar
  58. 58.
    Hutcheson KA, Bhayani MK, Beadle BM et al (2013) Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it. JAMA Otolaryngol Head Neck Surg 139(11):1127–1134PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Schindler A, Denaro N, Russi EG, Pizzorni N, Bossi P, Merlotti A, Bissetti MS, Numico G, Gava A, Orlandi E, Caspiani O (2015) Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus. Crit Rev Oncol Hematol 96(2):372–384PubMedCrossRefGoogle Scholar
  60. 60.
    Pauloski BR et al (2016) Efficacy of electrical stimulation and exercise for dysphagia in patients with head and neck cancer: a randomized clinical trial. Head Neck 38(Suppl 1):E1221–E1231PubMedGoogle Scholar
  61. 61.
    Krisciunas GP, Castellano K, McCulloch TM, Lazarus CL, Pauloski BR, Meyer TK et al (2017) Impact of compliance on dysphagia rehabilitation in head and neck cancer patients: results from a multi-center clinical trial. Dysphagia 32:327–336PubMedCrossRefGoogle Scholar
  62. 62.
    Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ et al (2004) Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 60:1425–1439PubMedCrossRefGoogle Scholar
  63. 63.
    Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M et al (2011) Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys 81:e93–e99PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M et al (2010) Intensity modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 28:2732–2738PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Christianen ME, Langendijk JA, Westerlaan HE, van de Water TA, Bijl HP (2011) Delineation of organs at risk involved in swallowing for radiotherapy treatment planning. Radiother Oncol 101(3):394–402PubMedCrossRefGoogle Scholar
  66. 66.
    Starmer HM, Quon H, Kumar R, Alcorn S, Murano E, Jones B et al (2015) The effect of radiation dose on swallowing: evaluation of aspiration and kinematics. Dysphagia 30:430–437PubMedCrossRefGoogle Scholar
  67. 67.
    Dale T, Hutcheson K, Mohamed AS, Lewin JS, Gunn GB, Rao AU et al (2016) Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol 118:304–314CrossRefGoogle Scholar
  68. 68.
    Wopken K, Bijl HP, Langendijk JA (2018) Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: a systematic review of literature. Radiother Oncol 126(1):56–67PubMedCrossRefGoogle Scholar
  69. 69.
    Lu W, Posner MR, Wayne P, Rosenthal DS, Haddad RI (2010) Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report. Integr Cancer Ther 9:284–290PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    van der Geer SJ, Kamstra JI, Roodenburg JL, van Leeuwen M, Reintsema H, Langendijk JA et al (2016) Predictors for trismus in patients receiving radiotherapy. Acta Oncol 55:1318–1323PubMedCrossRefGoogle Scholar
  71. 71.
    Bhrany AD, Izzard M, Wood AJ, Futran ND (2007) Coronoidectomy for the treatment of trismus in head and neck cancer patients. Laryngoscope 117:1952–1956PubMedCrossRefGoogle Scholar
  72. 72.
    Bensadoun RJ, Riesenbeck D, Lockhart PB, Elting LS, Spijkervet FK, Brennan MT (2010) A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer 18:1033–1038PubMedCrossRefGoogle Scholar
  73. 73.
    Buchbinder D, Currivan RB, Kaplan AJ, Urken ML (1993) Mobilization regimens for the prevention of jaw hypomobility in the radiated patient: a comparison of three techniques. J Oral Maxillofac Surg 51:863–7. 145PubMedCrossRefGoogle Scholar
  74. 74.
    Cohen EG, Deschler DG, Walsh K, Hayden RE (2005) Early use of a mechanical stretching device to improve mandibular mobility after composite resection: a pilot study. Arch Phys Med Rehabil 86:1416–1419PubMedCrossRefGoogle Scholar
  75. 75.
    Chua DT, Lo C, Yuen J, Foo YC (2001) A pilot study of pentoxifylline in the treatment of radiation-induced trismus. Am J Clin Oncol 24:366–369PubMedCrossRefGoogle Scholar
  76. 76.
    Nitzan DW, Azaz B, Constantini S (1992) Severe limitation in mouth opening following transtemporal neurosurgical procedures: diagnosis, treatment, and prevention. J Neurosurg 76:623–625PubMedCrossRefGoogle Scholar
  77. 77.
    Fujioka M, Daian T, Murakami R, Makino K (2000) Release of extra--articular ankylosis by coronoidectomy and insertion of a free abdominal flap: case report. J Craniomaxillofac Surg 28:369–372PubMedCrossRefGoogle Scholar
  78. 78.
    Chrcanovic BR, Reher P, Sousa AA, Harris M (2010) Osteoradionecrosis of the jaws—a current overview—part 1: physiopathology and risk and predisposing factors. Oral Maxillofac Surg 14:3–16PubMedCrossRefGoogle Scholar
  79. 79.
    Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14:199–212PubMedCrossRefGoogle Scholar
  80. 80.
    Marx RE (1983) Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 41(5):283–288PubMedCrossRefGoogle Scholar
  81. 81.
    Delanian S, Lefaix JL (2004) The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 73(2):119–131PubMedCrossRefGoogle Scholar
  82. 82.
    Sulaiman F, Huryn JM, Zlotolow IM (2003) Dental extractions in the irradiated head and neck patient: a retrospective analysis of Memorial Sloan-Kettering Cancer Center protocols, criteria, and end results. J Oral Maxillofac Surg 61:1123–1131PubMedCrossRefGoogle Scholar
  83. 83.
    Peterson DE, Doerr W, Hovan A, Pinto A, Saunders D, Elting LS et al (2010) Osteoradionecrosis in cancer patients: the evidence base for treatment dependent frequency, current management strategies, and future studies. Support Care Cancer 18:1089–1098PubMedCrossRefGoogle Scholar
  84. 84.
    Epstein J, Meij E, McKenzie M et al (1997) Postradiation osteonecrosis of the mandible: a long-term follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83:657PubMedCrossRefGoogle Scholar
  85. 85.
    Hulya Cankaya H, Pelin Guneri P (2010) Importance of a dental approach in head and neck cancer therapy. APJOH 2(1).  https://doi.org/10.1111/j.1743-7563.2005.00024.x CrossRefGoogle Scholar
  86. 86.
    Soares CJ, Castro CG, Neiva NA, Soares PV, Santos-Filho PC, Naves LZ et al (2010) Effect of gamma irradiation on ultimate tensile strength of enamel and dentin. J Dent Res 89:159–164PubMedCrossRefGoogle Scholar
  87. 87.
    Karmiol M, Walsh RF (1975) Dental caries after radiotherapy of the oral regions. J Am Dent Assoc 838-45(25):91Google Scholar
  88. 88.
    Gupta N, Pal M, Rawat S, Grewal MS, Garg H, Chauhan D et al (2015) Radiation-induced dental caries, prevention and treatment – a systematic review. Natl J Maxillofac Surg 6:160–166PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Rothwell BR (1987) Prevention and treatment of the orofacial complications of radiotherapy. J Am Dent Assoc 316-22(126):114Google Scholar
  90. 90.
    Kielbassa AM, Hinkelbein W, Hellwig E, Meyer--Luckel H (2006) Radiation related damage to dentition. Lancet Oncol 7:326–335PubMedCrossRefGoogle Scholar
  91. 91.
    Miguez PA, Pereira PN, Atsawasuwan P, Yamauchi M (2004) Collagen cross linking and ultimate tensile strength in dentin. J Dent Res 83:807–810PubMedCrossRefGoogle Scholar
  92. 92.
    Lertchirakarn V, Palamara JE, Messer HH (2001) Anisotropy of tensile strength of root dentin. J Dent Res 80:453–456PubMedCrossRefGoogle Scholar
  93. 93.
    Kassim N, Sirajuddin S, Biswas S, Rafi uddin S, Apine A (2015) Iatrogenic damage to the periodontium caused by radiation and radiotherapy. Open Dent J 9:182–186PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Andrews N, Griffiths C (2001) Dental complications of head and neck radiotherapy: part 2. Aust Dent J 46:174–182PubMedCrossRefGoogle Scholar
  95. 95.
    Jansma J, Vissink A, Spijkervet FK, Roodenburg JL, Panders AK, Vermey A et al (1992) Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 70:2171–2180PubMedCrossRefGoogle Scholar
  96. 96.
    Vanderpump MPJ, Tunbridge WMG (2002) Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid 12:839–847PubMedCrossRefGoogle Scholar
  97. 97.
    Alterio D, Jereczek-Fossa BA, Franchi B et al (2007) Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys 67:144–150PubMedCrossRefGoogle Scholar
  98. 98.
    Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM (2007) Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 68:1131–1139PubMedCrossRefGoogle Scholar
  99. 99.
    Hancock SL, McDougall IR, Constine LS (1995) Thyroid abnormalities after therapeutic external radiation. Int J Radiat Oncol Biol Phys 31:1165–1170PubMedCrossRefGoogle Scholar
  100. 100.
    Jereczek-Fossa BA, Alterio D, Jassem J, Gibelli B, Tradati N, Orecchia R (2004) Radiotherapy-induced thyroid disorders. Cancer Treat Rev 30:369–384PubMedCrossRefGoogle Scholar
  101. 101.
    Bakhshandeh M, Hashemi B, Mahdavi SR, Nikoofar A, Edraki HR, Kazemnejad A (2012) Evaluation of thyroid disorders during head-and-neck radiotherapy by using functional analysis and ultrasonography. Int J Radiat Oncol Biol Phys 83:198–203PubMedCrossRefGoogle Scholar
  102. 102.
    Lo Galbo AM, Kuik DJ, Lips P et al (2013) A prospective longitudinal study on endocrine dysfunction following treatment of laryngeal or hypopharyngeal carcinoma. Oral Oncol 950-5(51):49Google Scholar
  103. 103.
    Sunwoo JB, Herscher LL, Kroog GS et al (2001) Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 19:800–811PubMedCrossRefGoogle Scholar
  104. 104.
    Grande C (1992) Hypothyroidism following radiotherapy for head and neck cancer: multivariate analysis of risk factors. Radiother Oncol 25:31–36PubMedCrossRefGoogle Scholar
  105. 105.
    Tell R, Lundell G, Nilsson B et al (2004) Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 60:395–400PubMedCrossRefGoogle Scholar
  106. 106.
    Koc M, Capoglu I (2009) Thyroid dysfunction in patients treated with radiotherapy for neck. Am J Clin Oncol 32:150–153PubMedCrossRefGoogle Scholar
  107. 107.
    Posner MR, Ervin TJ, Millar D et al (1984) Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of head and neck. Laryngoscope 94:451–454PubMedCrossRefGoogle Scholar
  108. 108.
    Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRefGoogle Scholar
  109. 109.
    Murthy V, Narang K, Ghosh-Laskar S, Gupta T, Budrukkar A, Agrawal JP (2014) Hypothyroidism after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for head and neck cancers: prospective data from 2 randomized controlled trials. Head Neck 36(11):1573–1580PubMedCrossRefGoogle Scholar
  110. 110.
    Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA et al (2015) Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck 37:281–292PubMedCrossRefGoogle Scholar
  111. 111.
    Linskey ME, Johnstone PA (2003) Radiation tolerance of normal temporal bone structures: implications for gamma knife stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 57:196–200PubMedCrossRefGoogle Scholar
  112. 112.
    Hwang CF, Fang FM, Zhuo MY, Yang CH, Yang LN, Hsieh HS (2015) Hearing assessment after treatment of nasopharyngeal carcinoma with CRT and IMRT techniques. Biomed Res Int 2015:769806PubMedPubMedCentralGoogle Scholar
  113. 113.
    Lambert EM, Gunn GB, Gidley PW (2016) Effects of radiation on the temporal bone in patients with head and neck cancer. Head Neck 38:1428–1435PubMedCrossRefGoogle Scholar
  114. 114.
    Ho WK, Wei WI, Kwong DL, Sham JS, Tai PT, Yuen AP et al (1999) Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck 21:547–553PubMedCrossRefGoogle Scholar
  115. 115.
    Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P et al (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76(3 Suppl):S50–S57PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Honoré HB, Bentzen SM, Møller K, Grau C (2002) Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol 65:9–16PubMedCrossRefGoogle Scholar
  117. 117.
    Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR (2005) Prospective study of inner ear radiation dose and hearing loss in head-and neck cancer patients. Int J Radiat Oncol Biol Phys 61:1393–1402PubMedCrossRefGoogle Scholar
  118. 118.
    van der Putten L, de Bree R, Plukker JT, Langendijk JA, Smits C, Burlage FR et al (2006) Permanent unilateral hearing loss after radiotherapy for parotid gland tumors. Head Neck 28:902–908PubMedCrossRefGoogle Scholar
  119. 119.
    Chen J, Zhao Y, Zhou X, Tan L, Ou Z, Yu Y et al (2016) Methylprednisolone use during radiotherapy extenuates hearing loss in patients with nasopharyngeal carcinoma. Laryngoscope 126:100–103PubMedCrossRefGoogle Scholar
  120. 120.
    Sakamoto T, Shirato H, Takeichi N, Aoyama H, Kagei K, Nishioka T et al (2001) Medication for hearing loss after fractionated stereotactic radiotherapy (SRT) for vestibular schwannoma. Int J Radiat Oncol Biol Phys 50:1295–1298PubMedCrossRefGoogle Scholar
  121. 121.
    Kim JW, Kim DG, Paek SH, Chung HT, Kim YH, Han JH et al (2011) Efficacy of corticosteroids in hearing preservation after radiosurgery for vestibular schwannoma: a prospective study. Stereotact Funct Neurosurg 89:25–33PubMedCrossRefGoogle Scholar
  122. 122.
    Wei BP, Stathopoulos D, O’Leary S (2013) Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 7:CD003998Google Scholar
  123. 123.
    Spear SA, Schwartz SR, Dallan I, Fortunato S, Casani AP, Panicucci E et al (2011) Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngol Head Neck Surg 145:534–543PubMedCrossRefGoogle Scholar
  124. 124.
    Bennett MH, Kertesz T, Perleth M, Yeung P, Lehm JP (2012) Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev 10:CD004739PubMedGoogle Scholar
  125. 125.
    Low WK, Burgess R, Fong KW, Wang DY (2005) Effect of radiotherapy on retrocochlear auditory pathways. Laryngoscope 115:1823–1826PubMedCrossRefGoogle Scholar
  126. 126.
    Soh JM, D’Souza VD, Sarepaka GK, Ng WN, Ong CS, Low WK (2012) Cochlear implant outcomes: a comparison between irradiated and non-irradiated ears. Clin Exp Otorhinolaryngol 5(Suppl 1):S93–S98PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Chua CA, Low D, Tan TY, Yuen HW (2017) Cochlear implantation in an NPC patient post-irradiation presenting with electrode array extrusion through the posterior canal wall. Am J Otolaryngol 38:356–357PubMedCrossRefGoogle Scholar
  128. 128.
    le Nobel GJ, Hwang E, Wu A, Cushing S, Lin VY (2016) Vestibular function following unilateral cochlear implantation for profound sensorineural hearing loss. J Otolaryngol Head Neck Surg 45:38PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Wang JT, Wang AY, Psarros C, Da Cruz M (2014) Rates of revision and device failure in cochlear implant surgery: a 30-year experience. Laryngoscope 124:2393–2399PubMedCrossRefGoogle Scholar
  130. 130.
    Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O’Sullivan B (2017) Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 18(9):1221–1237PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Bernard C, Thomas K, Melania P, Padraig W, Waldron J, Payne D et al (2007) Five-year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 85(1):7–16CrossRefGoogle Scholar
  132. 132.
    Jens O, Sand HH, Lena S, Marie O et al (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomized controlled trial. Lancet 362:933–940CrossRefGoogle Scholar
  133. 133.
    Jens O, Kaylan MB, Naseem B, Rubina A, Agarwal JP, Kuddu M et al (2010) Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 11(6):503–504CrossRefGoogle Scholar
  134. 134.
    Budach W, Hehr T, Budach V, Belka C et al (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Ho MS, Ho CK, Ji CE, Geol LC et al (2014) A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1–2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol 110:98–103CrossRefGoogle Scholar
  136. 136.
    Kumiko K, Hiroaki K, Takahisa H, Hidehiro H et al (2013) Radiotherapy with fraction size of 2.25 Gy in T1–2 laryngeal and hypopharyngeal cancer. J Radiat Res 54:684–689CrossRefGoogle Scholar
  137. 137.
    Rikiya O, Masakazu H, Kouichi Y, Akihiro H et al (2011) Radiotherapy for glottic T1N0 carcinoma with slight hypofractionation and standard overall treatment time: importance of overall treatment time. Jpn J Clin Oncol 41(1):103–109CrossRefGoogle Scholar
  138. 138.
    Amado AC, Laurentiu B, Monteiro GI (2013) 3D conformal hypofractionated radical radiotherapy in early glottic cancer. Rep Pract Oncol Radiother 18:261–264PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Bahl A, Oinam AS, Kaur S, Verma R, Elangovan A, Bhandari S, Bakshi J, Panda N, Ghoshal S (2017) Evaluation of acute toxicity and early clinical outcome in head and neck cancers treated with conventional radiotherapy and simultaneous integrated boost arc radiotherapy. World J Oncol 8(4):117PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Santabarbara G, Maione P, Rossi A, Gridelli C (2016) Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy. Expert Opin Pharmacother 17(4):561–570PubMedCrossRefGoogle Scholar
  141. 141.
    Saito Y, Kobayashi M, Yamada T, Kasashi K, Honma R, Takeuchi S et al (2016) Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer 25(2):481–487PubMedCrossRefGoogle Scholar
  142. 142.
    McKibbin T, Cheng LL, Kim S, Steuer CE, Owonikoko TK, Khuri FR et al (2016) Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support Care Cancer 24:1789–1793PubMedCrossRefGoogle Scholar
  143. 143.
    Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA et al (2015) Sensorineural hearing loss in patients with head and neck cancer after chemotherapy and radiotherapy: a systemic review of the literature. Head Neck 37(2):281–292PubMedCrossRefGoogle Scholar
  144. 144.
    Meng DF, Sun R, Peng LX, Huang YS, Yang Q, Luo DH, Hu WH, Xie FY, Luo W, Zhao C, Guo L (2018) A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer 9(1):92PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D’Cruz AK, Banavali S, Pai PS (2017) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 36(11):1064–1072PubMedCrossRefGoogle Scholar
  146. 146.
    Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K (2007) Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98:1275–1280PubMedCrossRefGoogle Scholar
  147. 147.
    Vermorken JB, Trigo J, Hitt R, Koralweski P, Diaz-Rubio E, Rolland F et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 16:2171–2177CrossRefGoogle Scholar
  148. 148.
    Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRefGoogle Scholar
  149. 149.
    Chibaudal B, Lacave R, Lefevre M, Soussan P, Antoine M, Perie S et al (2015) Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil(ETPF) in patients with resectable nonmetastatic stage III and IV squamous cell carcinoma of the oropharynx. A GERCOR phase IIECHO-07 study. Cancer Med 4:721–731CrossRefGoogle Scholar
  150. 150.
    Valeriani M, Muni R, Osti MF, De Sanctis V, Minniti G, Ardito F et al (2012) Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy. Radiol Med 117:125–132PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME et al (2015) A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol 51:376–382PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Frampton JE (2010) Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 70(22):1987–2010PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Vijay V. Haribhakti
    • 1
  1. 1.Department of OncologySir HN Reliance Foundation HospitalMumbaiIndia

Personalised recommendations